Francois Nader - 10 May 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
10 May 2022
Net transactions value
+$921
Form type
4
Filing time
12 May 2022, 16:22:00 UTC
Previous filing
02 May 2022
Next filing
13 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $435,897 +23,100 +3286% $18.87 23,803 10 May 2022 Direct F1
transaction MRNA Common Stock Sale $434,976 -3,196 -13% $136.10 20,607 10 May 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -23,100 -58% $0.000000 16,620 10 May 2022 Common Stock 23,100 $18.87 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022.
F2 Represents the number of shares sold by the Reporting Person to cover the payment of the exercise price of the option.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.10 to $136.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 This option is fully vested and exercisable.